F Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, Sumeet Bhanvadia, Kirk A Keegan, Shalaka Hampras, Hussein Sweiti, John C Maffeo, Shu Jin, Albert Chau, Donald L Reynolds, Crysti Iarossi, April Kelley, Xiang Li, Katharine A Stromberg, J P Michiel Sedelaar, Jessica J O Steenbruggen, Diederik M Somford, J Alfred Witjes
BACKGROUND AND OBJECTIVE: Patients with intermediate-risk non-muscle-invasive bladder cancer (IR NMIBC) have a high risk of recurrence and need effective therapies to reduce the risk of disease recurrence or progression. This phase 1b study (NCT02720367) assessed the safety and tolerability of TAR-200, an intravesical drug delivery system, in participants with IR NMIBC. METHODS: Participants with recurrent IR NMIBC were eligible. Participants received either two 7-d or two 21-d TAR-200 dosing cycles over a 4-6-wk period in a marker lesion/ablation design...
April 2024: European urology open science